Recently, increasing evidence has suggested that IL-17 expression was elevated in multiple cancer types, including prostate cancer [32], colorectal cancer [33], hepatocellular carcinoma [34], breast cancer [35], ovarian cancer [36] and NSCLC [37]. This evidence concerns the gene IL17A and breast carcinoma.